Related Experiment Video

Updated: May 23, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Latest drug developments in the field of cardiovascular disease

Craig S Stern1, Jason Lebowitz

  • 1Pro Pharma Pharmaceutical Consultants Inc, Northridge; and University of Southern California School of Pharmacy, Los Angeles, California, USA.

The International Journal of Angiology : Official Publication of the International College of Angiology, Inc
|April 6, 2012
PubMed

Insights

Cardiovascular disease remains a leading cause of death, yet new drug development is limited. This review examines emerging cardiovascular agents and the innovative models driving their development.

Area of Science:

  • Cardiology
  • Pharmacology
  • Drug Development

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality globally.
  • The development of new CVD medications has lagged significantly in recent years.
  • In 2008 and 2009, only a few new cardiovascular drugs were approved, contrasting with other fields like oncology.

Purpose of the Study:

  • To review novel agents in the cardiovascular drug pipeline.
  • To explore the innovative models and approaches used in developing new cardiovascular therapies.
  • To provide insight into the future landscape of cardiovascular drug development.

Main Methods:

  • Literature review of current cardiovascular drug development.
  • Analysis of agents within the existing drug pipeline.
  • Discussion of models employed in the development of new cardiovascular agents.

Main Results:

  • The cardiovascular drug pipeline shows limited new entrants compared to other therapeutic areas.
  • Several novel agents are under investigation for cardiovascular conditions.
  • Various innovative models are being utilized to accelerate the development of these agents.

Conclusions:

  • Despite the challenges, there is ongoing research into new cardiovascular medications.
  • The development models discussed offer potential pathways for future drug approvals.
  • Continued innovation in drug development is crucial to address the burden of cardiovascular disease.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...